Compare ADMA Biologics Inc (ADMA) vs Box Inc (BOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Box Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Box Inc trades at $32.86 (market cap $4.65B). The key difference: Box Inc is far larger — about 2.1× ADMA Biologics Inc's market cap, and Box Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BOX | |
|---|---|---|
Market Cap | $2.18B | $4.65B |
Sector | Health | Technology |
52-Week High | $20.38 | $33.60 |
52-Week Low | $7.60 | $21.37 |
Enterprise Value | $2.25B | $5.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
BOX Inc. (NYSE: BOX) trades at $33.24, up 4.36% today, showing strong momentum near resistance levels. The company delivered solid Q1 2026 earnings beat with EPS of $0.37 versus $0.36 expected, continuing positive earnings surprises. Revenue growth accelerated to $1.09 billion in 2025 with net income margin expanding to 22.43%. Technical indicators show bullish momentum with the stock trading above key support levels and moving averages signaling strength.
BOX presents growth potential with strong revenue expansion and improving profitability, supported by recent enterprise contract wins like Quintas Energy's AI platform selection. However, elevated P/E ratio of 51.94 suggests premium valuation, while negative equity and high debt levels warrant monitoring. Analyst consensus remains bullish with $37 price target, representing 11% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
